Cantor Fitzgerald initiated coverage of United Therapeutics (UTHR) with an Overweight rating and $405 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Maintaining Market Position: United Therapeutics’ Tyvaso DPI Amidst Competition and Future Growth Prospects
- Liquidia price target raised to $23 from $20 at Wells Fargo
- Hold Rating for United Therapeutics Amid Competitive Pressures from LQDA’s Yutrepia
- Liquidia price target raised to $37 from $29 at BTIG
- Liquidia price target raised to $31 from $27 at Jefferies